High-Purity Bortezomib API: Targeted Therapy for Multiple Myeloma and Mantle Cell Lymphoma
Discover the precision of Bortezomib in combating challenging blood cancers.
Get a Quote & SampleProduct Core Value
Bortezomib API
Bortezomib, a critical Active Pharmaceutical Ingredient (API) with CAS number 179324-69-7, represents a significant advancement in targeted cancer therapy. Its primary application lies in the treatment of challenging hematological malignancies such as multiple myeloma and mantle cell lymphoma.
- Discover the efficacy of bortezomib multiple myeloma treatment, a proven therapy for patients with relapsed or refractory conditions.
- Explore the role of proteasome inhibitor API in disrupting cancer cell signaling pathways, leading to apoptosis and tumor growth inhibition.
- Learn about the high purity bortezomib CAS 179324-69-7, ensuring consistent quality and therapeutic effectiveness for critical pharmaceutical applications.
- Understand how bortezomib for cancer patients offers a targeted approach, potentially minimizing side effects compared to traditional chemotherapy.
Key Advantages
Targeted Action
Understand the cancer drug bortezomib mechanism: it uniquely targets proteasomes within cancer cells, leading to their demise without broadly affecting healthy tissues.
Improved Patient Outcomes
The use of mantle cell lymphoma targeted therapy with Bortezomib has shown promising results, offering hope and improved quality of life for patients.
High Purity & Certification
As a leading bortezomib supplier in China, we ensure our product meets stringent quality standards, including GMP, HSE, ISO 9001, and USP certifications.
Key Applications
Multiple Myeloma Treatment
Bortezomib is a cornerstone in the treatment of multiple myeloma, particularly for patients who have relapsed or become refractory to previous therapies, showcasing its value in bortezomib multiple myeloma treatment.
Mantle Cell Lymphoma Therapy
The drug provides a vital option for patients diagnosed with mantle cell lymphoma, offering a targeted approach as part of their treatment plan.
Research & Development
Beyond clinical use, Bortezomib serves as a crucial compound in ongoing research for new cancer treatments and understanding cellular mechanisms.
Pharmaceutical Intermediate
The high purity of this API makes it an essential intermediate in the synthesis of complex pharmaceutical compounds aimed at combating various diseases.